Best Immunotherapy Companies in Seoul, South Korea
The 44 best Immunotherapy companies in Seoul, South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cellid.
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Immunotherapy companies in Seoul
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cellid Developer of personalized vaccines to treat cancer and infectious diseases 32Patents top 32%Funding top 35%Innovation top 40%Moat top 45% All 8 signals ▾Patentstop 32% Fundingtop 35% Innovationtop 40% Moattop 45% Marketbottom 48% Globalbottom 35% Fin. healthbottom 35% Techbottom 22% Patents: 32 patents matched (strict assignee match) · 26 filings since 2022 vs 4 in 2017-21 Funding: Raised $2.4B across 1 rounds · 1 rounds over 12 yrs (0.1/yr) rank vs industry peers · Fliar Intelligence Index 32/100 | $2.4B | 122 mo ago | Public | — | 2014 | PHPNginxNaver Analytics+5 | 32 patents NK cell-based cancer vaccines and replication-deficient adenoviral vector platforms | — |
| 2 | Wellmarker Bio Developer of biomarker-based therapeutics for the treatment of cancer | $45M | 85 mo ago | Series B | Dong Hoon Co-Founder & Co-CEO | 2016 | — | 85 patents Patents concentrated in chemistry & materials | — |
| 3 | Aston Sci. Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases | $40M | 56 mo ago | Series C | — | 2018 | — | — | — |
| 4 | LISCure Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases | $26M | 66 mo ago | Series B | Hwaseop Chin CEO | 2018 | — | — | — |
| 5 | Tikaros Developer of immunotherapies for the treatment of cancer | $24M | 59 mo ago | Series C | Kyungho Choi Co-Founder | 2018 | Windows ServerYouTubeMicrosoft ASP.NET+12 | — | — |
| 6 | Must Bio Developer of immunotherapeutics for cancer treatment 27Funding top 29%Talent bottom 49%Market bottom 36%Global bottom 29% All 4 signals ▾Fundingtop 29% Talentbottom 49% Marketbottom 36% Globalbottom 29% Funding: Raised $23.5M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 27/100 | $24M | 5 mo ago | Series C | Kim Seop CEO | 2021 | — | — | — |
| 7 | Progen Developer of immunotherapies for immune diseases and cancer 62Growth top 5%Partners top 18%News top 19%Moat top 25% All 10 signals ▾Growthtop 5% Partnerstop 18% Newstop 19% Moattop 25% Patentstop 39% Innovationtop 48% Fundingbottom 49% Talentbottom 49% Marketbottom 48% Globalbottom 36% Partners: 5 contract events in 12 mo · Named contractor/client in 5 deals rank vs industry peers · Fliar Intelligence Index 62/100 | $23M | 40 mo ago | Series B | Jong Kim CEO | 2000 | — | 73 patents Engineered Fc-fusion antibody therapeutics and cytokine variant proteins for medical use | — |
| 8 | Eutilex Developing T cell-based therapeutics and antibodies for the treatment of cancer. | $18M | 116 mo ago | Public | Byoung Kwon Founder & CEO | 2015 | PHPGSAPApache HTTP Server+6 | 191 patents Immuno‑oncology therapeutics: checkpoint antibodies, bispecifics, CAR‑T, and immune‑adjuvant formulations. | — |
| 9 | Daan Biotherapeutics Developer of therapeutics for cancer treatment 19Moat top 38%Talent top 38%Patents top 43%Funding top 44% All 9 signals ▾Moattop 38% Talenttop 38% Patentstop 43% Fundingtop 44% Innovationbottom 47% Globalbottom 40% Growthbottom 35% Techbottom 31% Marketbottom 19% Moat: Editorial + unicorn rating 4/10 · IP moat: 8 patents Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 19/100 | $17M | 30 mo ago | Series A | J Han Founder | 2020 | GnuboardMySQLPHP+18 | 8 patents Targeted immunotherapy: CEACAM5-specific antibodies and engineered T‑cell receptors for cancer. | — |
| 10 | Neogen TC Developer of cell therapies for the treatment of cancer | $13M | 64 mo ago | Series A | Heejin Lee CEO | 2020 | — | — | — |
| 11 | Boostimmune Developer of therapeutics for cancer treatment | $13M | 50 mo ago | Series A | Tadatsugu Taniguchi Co-Founder | 2021 | — | 10 patents TCTP-based cancer biomarkers and therapeutic agents for tumor immune modulation | — |
| 12 | EyeGene Developer of immune vaccines and diagnostic systems for eye disorders | $12M | 104 mo ago | Public | — | 2000 | GnuboardMySQLPHP+10 | 164 patents Peptide multiplex diagnostics and mRNA/viral protein vaccine delivery technologies. | — |
| 13 | Vaxdigm Developer of vaccines and immunotherapies for infectious disease 14Moat top 38%Patents top 45%Innovation top 50%Funding bottom 41% All 6 signals ▾Moattop 38% Patentstop 45% Innovationtop 50% Fundingbottom 41% Globalbottom 31% Marketbottom 26% Moat: Editorial + unicorn rating 4/10 · IP moat: 13 patents Patents: 13 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 14/100 | $2M | 22 mo ago | Series A | — | 2021 | — | 13 patents Viral nucleocapsid-based platforms for protein expression and self-assembling nanoparticle vaccines | — |
Top 12 Immunotherapy companies in Seoul
#1
Series C · Seoul, Seoul · founded 2021 · 18 employees$23.5Mraised▾
Developer of immunotherapeutics for cancer treatment. It offers multi-specific antibodies which include MB101, MB201, MB301, and MB401 for the treatment of multiple cancer. It offers multi-antibody platform technology to develop multiple antibodies.
- Mar 2026Series C$23.5M
- Series A—
- Series B—
#2
Public · Seoul, Seoul · founded 2014 · 68 employees$2.4Braised▾
Cellid is involved in developing personalized vaccines for treating cancer and infectious diseases. They have developed a platform, CeliVax, which activates the anti-cancer immune system which allows the immune cells to detect and kill cancer cells. Their pipeline products include BVAC-C is being investigated for cervical, head, and neck cancer, and BVAC-B for gastric cancer. The candidates are in phase II clinical trial.
- 2016Series A—
- 2015Series A—
- 2014Series A—
- 2014Series A—
#3
Series A · Seoul, Seoul · founded 2021 · 9 employees$1.9Mraised▾
Developer of vaccines and immunotherapies for infectious disease. It offers synthetic antigen vaccines using microorganisms and animal cells for rapid protein development and production, DNA vaccine, and mRNA vaccine for covid and viral diseases.
- Oct 2024Series A$1.9M
#4
Series A · Seoul, Seoul · founded 2020 · 4 employees$17.2Mraised▾
Developer of therapeutics for cancer treatment. It offers immune-based cell therapies against lung cancer that expresses T Cell Receptors(TCR) based on natural killer cells and target EGFR mutations.
- Jan 2024Series A$17.2M
#5
Series B · Seoul, Seoul · founded 2000$22.8Mraised▾
Developer of immunotherapies for immune diseases and cancer. It offers a pipeline of drug candidates which include PG-102 for obesity, PG-208, PG-202, and others for oncology. It is based on NTIG (Neo Tri-ImmunoGlobulin) and Cyt-NTIG technology that overcomes the systemic side effects of cytokines through specific targeting.
- Apr 2023Series B$22.8M
#6
Series C · Seoul, Seoul · founded 2018 · 24 employees$40Mraised▾
Developer of therapeutic solutions for the treatment of cancer, CNS diseases, and geriatric diseases. The company's flagship product AST-021p that is an HSP90 peptide vaccine helps in the treatment of cancer. It has also developed AST-05X that is a GCN2 inhibitor that helps in treating cancer metabolism. Other products include AST-06X for CNS disorders, AST-301, AST-023 for cancer treatment, and more.
- Dec 2021Series C$22.7M
#7
Series B · Seoul, Seoul · founded 2016 · 58 employees$45.2Mraised▾
Developer of biomarker-based therapeutics for the treatment of cancer. The company has a drug pipeline of small molecules (WM-S1), antibodies(WM-A1), and protein (WM-P1) therapies in the preclinical stage targeting various cancers including colon, breast, NSLC, liver, and prostate. WM-S1 is CRG targeted inhibitor and WM-A1 is an antibody targeting cancer immunotherapy-related genes (CMG).
- Jul 2019Series B$16M
- Nov 2018Series A$25M
- Apr 2018Seed$4.2M
#8
Series C · Seoul, Seoul · founded 2018$24.4Mraised▾
Developer of immunotherapies for the treatment of cancer. The company has CAR-T gene-modified cell therapies which include TC011, TC012 for lymphoma, TC002, TC003 for solid cancer, and TC007 for multiple myeloma. These therapies are based on clamping-based immunological synapse potentiating CAR technology.
- Aug 2021Series C$21.5M
#9
Series A · Seoul, Seoul · founded 2021 · 5 employees$13.2Mraised▾
Developer of therapeutics for cancer treatment. It offers multiple drug candidates that include antibody-drug conjugates, immune-stimulating antibody conjugates, and others that modulate the patient's immune cells and immune system.
- Jun 2022Series A$13.2M
- Aug 2021Seed—
#10
Series B · Seoul, Seoul · founded 2018 · 7 employees$26Mraised▾
Developer of bacteria-mediated immunotherapeutic drugs for multiple diseases. It is used for treating cancer (LB-100 (preclinical), LB-200, LB-300) in the in vivo stage, neurodegenerative diseases (LB-400 (preclinical), LB-500) in the in vivo stage, rheumatoid arthritis (LB-600), and NASH (LB-700). The company has also developed leads for the prevention of hair growth (LB-100f), liver disease (LB-200f), osteoarthritis (LB-300f), and obesity (LB-400f).
- Feb 2021Series B$21M
- Jul 2019Seed$5M
#11
Series A · Seoul, Seoul · founded 2020$13.3Mraised▾
Developer of cell therapies for the treatment of cancer. The company focuses on developing immune T-cell therapy based on a new antigen discovery platform. The company has developed a pipeline for breast and lung cancer.
- Apr 2021Series A$13.3M
#12
Public · Seoul, Seoul · founded 2015 · 103 employees$18Mraised▾
Eutilex is developing T cell-based therapeutics and antibodies for the treatment of cancer. Its adoptive T cell therapy pipeline include EBViNT Cells (EBV/LMP2A-specific T cells) to treat Epstein-Barr Virus (EBV)-positive cancers (Phase 2b); WTiNT cell therapy (WT1-specific T cell therapeutics) for glioblastomas (Phase 1) and TERTiNT cell therapy (hTERT-specific T cell therapeutics) for various types of solid cancers (phase 1). The company is also developing CAR-T cell therapies and monoclonal antibodies for the treatment of wide range of cancers (preclinical).
- Dec 2016Series A$18M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Immunology in Seoul is moving
A read on the academic research around Immunology in Seoul — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 179 papers.
- Seoul National University96
- Seoul National University Hospital41
- The Catholic University of Korea Seoul St. Mary\'s Hospital26
- Seoul National University Bundang Hospital22
- Hanyang University Seoul Hospital11
- Immunotherapy14
- Immune system11
- Tumor microenvironment10
- Cancer immunotherapy6
- T cell6
- Immune system1→44
- Internal medicine1→12
- Cancer1→8
- Autoimmune disease1→4
- Immunotherapy1→9
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.